Cedars-Sinai Study Leverages Oncology Research to Improve Outcomes for Patients with Aggressive Prolactinomas

Cedars-Sinai Study Leverages Oncology Research to Improve Outcomes for Patients with Aggressive Prolactinomas

As an endocrinologist and associate professor at Cedars-Sinai, Cooper is accustomed to treating patients with pituitary tumors. For a patient with a typical prolactinoma, the current standard of treatment is dopamine agonist oral medications and surgery. “Pituitary tumors are usually benign and respond well to these therapies,” says Cooper, “but 10%-15% can be resistant to

As an endocrinologist and associate professor at Cedars-Sinai, Cooper is accustomed to treating patients with pituitary tumors. For a patient with a typical prolactinoma, the current standard of treatment is dopamine agonist oral medications and surgery.

“Pituitary tumors are usually benign and respond well to these therapies,” says Cooper, “but 10%-15% can be resistant to typical therapies. I was seeing a lot of these patients in clinic and realized we did not have a lot of options for escalating treatment once we had maximized their standard therapies.”

The lack of further treatment options was distressing to patients, and Cooper wondered how the science might be advanced to improve outcomes for those resistant to current therapies. Cooper and the interdisciplinary team at the Cedars-Sinai Pituitary Center are focused on delivering the most effective, tailored therapeutic options for their patients informed by the most recent research, and she believed there could be better options for patients who present with aggressive prolactinomas.

Building on research started in the oncological field that developed medications that target the epidermal growth factor receptor (EGFR) pathway, Cooper and her research partners identified a medication protocol that uses the same pathway to reduce prolactin and also inhibit aggressive prolactinoma growth.

“The EGFR pathway is well known to oncologists,” explains Cooper. “They have developed an armamentarium of medications to target this pathway, but I realized the pathway was under-studied in the context of pituitary tumors.”

For this research study, Cooper and her colleagues chose the drug lapatinib to test reduction in prolactin and tumor size. Lapatinib is a tyrosine kinase inhibitor (TKI) that targets the EGFR pathway and Erb-B2 receptor. Collaborating with postdoctoral researchers, they showed that the EGFR pathway was active and could be inhibited with TKIs in cellular and animal models of prolactinomas. Further, pituitary surgical colleagues assisted with careful collection of prolactinoma samples from patients who were not responding to traditional therapies.

“We collected tissue from human prolactinomas and saw that, with lapatinib, the prolactin levels went down. We confirmed that the EGFR pathway is indeed active in patients with prolactinoma tumors.”

Source: https://www.cedars-sinai.org/blog/oncology-research-improve-patient-outcomes.html

admin
ADMINISTRATOR
PROFILE

Posts Carousel

Leave a Comment

Your email address will not be published. Required fields are marked with *

Latest Posts

Top Authors

Most Commented

Featured Videos

php shell hacklink php shell seo instagram takipçi satın al php shell antika alanlar ucuz takipçi satın al plak alanlar okey oyna sohbet